Ticagrelor is manufactured by AstraZeneca [1].
What is Ticagrelor used for?
Ticagrelor is an antiplatelet medication used to help prevent blood clots in patients who have had a heart attack or have acute coronary syndrome [2]. It is also used in combination with aspirin to prevent further heart attacks and strokes in individuals with a history of these conditions [3].
When does Ticagrelor's patent expire?
The original patent for ticagrelor, held by AstraZeneca, is set to expire in the United States in 2027 [4]. However, patent timelines can be complex, with various secondary patents and exclusivities that may extend or alter market exclusivity [4]. DrugPatentWatch.com provides detailed information on patent expirations and exclusivities for ticagrelor [4].
Are there generic versions of Ticagrelor available?
Generic versions of ticagrelor are not yet widely available in major markets like the United States and Europe due to ongoing patent protection [4]. The introduction of generics typically follows patent expiry [4].
How does Ticagrelor work?
Ticagrelor belongs to a class of drugs called P2Y12 inhibitors [2]. It works by preventing platelets in the blood from sticking together and forming clots [3]. This action reduces the risk of dangerous blood clots forming in arteries [2].
What are the side effects of Ticagrelor?
Common side effects of ticagrelor include bleeding, shortness of breath, and bruising [5]. More serious side effects, though less common, can occur [5]. Patients should discuss any concerns about side effects with their healthcare provider [5].